Evidence map›Paper›PMID 22570689›Full record

ArticlePloS one2012

Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.

Suresh de Silva, Vicente Planelles, Li Wu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. HIV reprograms host mNature communications · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.International journal of molecular sciences · 2017
    Review
  12. Article
  13. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Suresh de SilvaCenter for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
Vicente Planelles
Li Wu
The Ohio State University · USUniversity of Utah · US

Funding

Mechanisms Underlying Dendritic Cell-mediated HIV TransmissionR01AI068493 · NIAID · OHIO STATE UNIVERSITY · PI WU, LI · 2006 to 2010
$1.5M
The role of UBE2V1 in HIV-1 restriction in primary monocytesR21AI098524 · NIAID · OHIO STATE UNIVERSITY · PI WU, LI · 2012 to 2013
$419k
Exploring Postentry Restriction of HIV Infection in Human MonocytesR21AI078762 · NIAID · OHIO STATE UNIVERSITY · PI WU, LI · 2009 to 2010
$419k
Novel host proteins in the HIV-1 preintegration complexesR21AI102822 · NIAID · OHIO STATE UNIVERSITY · PI WU, LI · 2012 to 2013
$406k
NIAID NIH HHS AI068493NIAID NIH HHS AI078762NIAID NIH HHS AI098524NIAID NIH HHS R01 AI068493NIAID NIH HHS R21 AI078762NIAID NIH HHS R21 AI098524NIAID NIH HHS R21 AI102822
6 · The paper itself

Abstract

The Vpr protein of human immunodeficiency virus type 1 (HIV-1) contributes to viral replication in non-dividing cells, specifically those of the myeloid lineage. However, the effects of Vpr in enhancing HIV-1 infection in dendritic cells have not been extensively investigated. Here, we evaluated the role of Vpr during infection of highly permissive peripheral blood mononuclear cells (PBMCs) and CD4(+) T-cells and compared it to that of monocyte-derived dendritic cells (MDDCs), which are less susceptible to HIV-1 infection. Infections of dividing PBMCs and non-dividing MDDCs were carried out with single-cycle and replication-competent HIV-1 encoding intact Vpr or Vpr-defective mutants. In contrast to previous findings, we observed that single-cycle HIV-1 infection of both PBMCs and MDDCs was significantly enhanced in the presence of Vpr when the viral stocks were carefully characterized and titrated. HIV-1 DNA quantification revealed that Vpr only enhanced the reverse transcription and nuclear import processes in single-cycle HIV-1 infected MDDCs, but not in CD4(+) T-cells. However, a significant enhancement in HIV-1 gag mRNA expression was observed in both CD4(+) T-cells and MDDCs in the presence of Vpr. Furthermore, Vpr complementation into HIV-1 virions did not affect single-cycle viral infection of MDDCs, suggesting that newly synthesized Vpr plays a significant role to facilitate single-cycle HIV-1 infection. Over the course of a spreading infection, Vpr significantly enhanced replication-competent HIV-1 infection in MDDCs, while it modestly promoted viral infection in activated PBMCs. Quantification of viral DNA in replication-competent HIV-1 infected PBMCs and MDDCs revealed similar levels of reverse transcription products, but increased nuclear import in the presence of Vpr independent of the cell types. Taken together, our results suggest that Vpr has differential effects on single-cycle and spreading HIV-1 infections, which are dependent on the permissiveness of the target cell.

Indexed as

Virus ReplicationCarrier ProteinsCell LineCells, CulturedDendritic CellsDNA, ViralGenes, gagGene SilencingHIV-1HumansLeukocytes, MononuclearProtein Serine-Threonine KinasesProvirusesRNA InterferenceRNA, MessengerT-LymphocytesCarrier ProteinsDCAF1 protein, humanDNA, ViralProtein Serine-Threonine KinasesRNA, MessengerUbiquitin-Protein LigasesViral Envelope Proteinsvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1

Identifiers

PMID22570689
PMCPMC3343049
OpenAlexW1512035175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.